Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus.

Summary Aims To evaluate the long-term effectiveness of Humalog® insulin in lowering post meal glucose excursions. Methods Twenty young subjects with Type 1 diabetes mellitus (DM) who had received insulin-lispro (Humalog®) for a least 1 year (mean ± SD 1.8 ± 1.6 years) were studied on two occasions, 3–14 days apart. They consumed a similar breakfast consisting of 450–600 kCal having fasted overnight. The same amount of human soluble Humulin® Regular or Humalog® insulin was given 10 min before the meal in a randomized, double-blind fashion. Results Postprandial glucose excursions at 30, 60, and 120 min were significantly lower (P < 0.001, ancova) when subjects received Humalog® as compared to human soluble insulin. Serum-free insulin levels were significantly higher (P < 0.001, anova) at 30 and 60 min when subjects received Humalog® as compared with human soluble insulin. Humalog® antibody levels after up to 5.4 years of receiving Humalog® insulin were not elevated beyond the values at 1 year. Conclusions We conclude that Humalog® insulin is effective in lowering postprandial glucose excursions even after up to 5.4 years of treatment.